Previous Section
Drug Therapy
1. Pentostatin, cyclophosphamide, and rituximab is an active, well-tolerated regimen for patients with previously treated chronic lymphocytic leukemia.
- Author
- Lamanna N; Kalaycio M; Maslak P; Jurcic JG; Heaney M; Brentjens R; Zelenetz AD; Horgan D; Gencarelli A; Panageas KS; Scheinberg DA; Weiss MA;
- Institution
- Leukemia Service, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA.
- Journal
- J Clin Oncol. 2006 Apr 1;24(10):1575-81. Epub 2006 Mar 6.
- Abstract URL
- Click here to view abstract
2. A retrospective comparison of three sequential groups of patients with Recurrent/Refractory chronic lymphocytic leukemia treated with fludarabine-based regimens.
- Author
- Wierda W; O'brien S; Faderl S; Ferrajoli A; Wang X; Do KA; Garcia-Manero G; Thomas D; Cortes J; Ravandi-Kashani F; Giles F; Lerner S; Kantarjian H; Keating M;
- Institution
- Department of Leukemia, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA. wwierda@mdanderson.org
- Journal
- Cancer. 2006 Jan 15;106(2):337-45.
- Abstract URL
- Click here to view abstract
3. Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapy.
- Author
- Byrd JC; Gribben JG; Peterson BL; Grever MR; Lozanski G; Lucas DM; Lampson B; Larson RA; Caligiuri MA; Heerema NA;
- Institution
- Division of Hematology-Oncology, Department of Internal Medicine, The Ohio State University, Columbus, OH 43210, USA. john.byrd@osumc.edu
- Journal
- J Clin Oncol. 2006 Jan 20;24(3):437-43. Epub 2005 Dec 12.
- Abstract URL
- Click here to view abstract
4. An observational study of once weekly intravenous ganciclovir as CMV prophylaxis in heavily pre-treated chronic lymphocytic leukemia patients receiving subcutaneous alemtuzumab.
- Author
- Visani G; Mele A; Guiducci B; D'Adamo F; Leopardi G; Barulli S; Malerba L; Lucesole M; Sparaventi G; Piccaluga PP; Guernaccini E; Agostinelli F; Isidori A;
- Institution
- Department of Hematology, San Salvatore Hospital, Pesaro, Italy. pesarohematology@yahoo.it
- Journal
- Leuk Lymphoma. 2006 Dec;47(12):2542-6.
- Abstract URL
- Click here to view abstract
5. Cytomegalovirus reactivation in patients with chronic lymphocytic leukemia treated with alemtuzumab: prophylaxis vs. pre-emptive strategies for prevention.
- Author
- Worth LJ; Thursky KA;
- Institution
- Department of Infectious Diseases, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia. leon.worth@petermac.org
- Journal
- Leuk Lymphoma. 2006 Dec;47(12):2435-6.
6. Pentostatin, cyclophosphamide, and rituximab regimen in older patients with chronic lymphocytic leukemia.
- Author
- Shanafelt TD; Lin T; Geyer SM; Zent CS; Leung N; Kabat B; Bowen D; Grever MR; Byrd JC; Kay NE;
- Institution
- Department of Internal Medicine, Division of Hematology, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA. shanafelt.tait@mayo.edu
- Journal
- Cancer. 2007 Jun 1;109(11):2291-8.
- Abstract URL
- Click here to view abstract
7. Alemtuzumab in combination with high-dose methylprednisolone is a logical, feasible and highly active therapeutic regimen in chronic lymphocytic leukaemia patients with p53 defects.
- Author
- Pettitt AR; Matutes E; Oscier D;
- Institution
- Journal
- Leukemia. 2006 Aug;20(8):1441-5. Epub 2006 Jun 1.
8. Clinical outcomes and prognostic factors in patients with Richter's syndrome treated with chemotherapy or chemoimmunotherapy with or without stem-cell transplantation.
- Author
- Tsimberidou AM; O'Brien S; Khouri I; Giles FJ; Kantarjian HM; Champlin R; Wen S; Do KA; Smith SC; Lerner S; Freireich EJ; Keating MJ;
- Institution
- Department of Leukemia, Blood and Marrow Transplantation, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA. atsimber@mdanderson.org
- Journal
- J Clin Oncol. 2006 May 20;24(15):2343-51.
- Abstract URL
- Click here to view abstract
9. Fludarabine, cyclophosphamide, and rituximab for the treatment of patients with chronic lymphocytic leukemia or indolent non-Hodgkin lymphoma.
- Author
- Tam CS; Wolf M; Prince HM; Januszewicz EH; Westerman D; Lin KI; Carney D; Seymour JF;
- Institution
- Leukemia/Lymphoma Service, Hematology Service, Peter MacCallum Cancer Center, The Alfred Hospital, University of Melbourne, Victoria, Australia.
- Journal
- Cancer. 2006 Jun 1;106(11):2412-20.
- Abstract URL
- Click here to view abstract
10. The natural history of fludarabine-refractory chronic lymphocytic leukemia patients who fail alemtuzumab or have bulky lymphadenopathy.
- Author
- Tam CS; O'Brien S; Lerner S; Khouri I; Ferrajoli A; Faderl S; Browning M; Tsimberidou AM; Kantarjian H; Wierda WG;
- Institution
- Department of Leukemia and Stem Cell Transplantation, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.
- Journal
- Leuk Lymphoma. 2007 Oct;48(10):1931-9.
- Abstract URL
- Click here to view abstract
Next: Clinical Trials
